drugset / Trial / NCT02213315
A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects
RandomizedDouble-blindTreatment
Summary
A phase 1 randomized, double blind single-dose study to evaluate the PK and immunogenicity of single SC 100 and 150 mg doses of mavrilimumab in healthy adult Japanese subjects.
Timeline
- Start
- 2014-07
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mavrilimumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Mavrilimumab | Monoclonal antibody | 150 mg | Subcutaneous |
Indications
No indication recorded.